Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aminoglutethimide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 known ✓ | P11511 | 19/20 | 0.78 |
| ▸ | CYP11A1 known ✓ | P05108 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.78 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.78 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.78 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.78 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.78 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.78 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glutethimide SCHEMBL16041753 | 0.89 | CYP19A1 (0.59) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| Aminoglutethimide SCHEMBL4306 | 0.88 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| Aminoglutethimide SCHEMBL116988 | 0.88 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| Aminoglutethimide SCHEMBL1230613 | 0.88 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| Aminoglutethimide SCHEMBL7728932 | 0.88 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| Aminoglutethimide SCHEMBL28457203 | 0.87 | CYP19A1 (0.97) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| Aminoglutethimide SCHEMBL28119771 | 0.86 | CYP19A1 (0.94) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| Aminoglutethimide SCHEMBL11699322 | 0.85 | CYP19A1 (0.86) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| Aminoglutethimide SCHEMBL27862969 | 0.84 | CYP19A1 (0.80) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| Aminoglutethimide SCHEMBL28329350 | 0.83 | CYP19A1 (0.89) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 403 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023044463-A1 | SILK FIBROIN DERIVED BRUSH-LIKE POLYMERS | UNIVERSITY OF CONNECTICUT (US) | 2023-03-23 | — | — | WO | claimed |
| WO-2024145272-A1 | MODULAR BONE SCAFFOLD | TRUSTEES OF TUFTS COLLEGE (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024097977-A1 | SILK NANOPARTICLE SYNTHESIS: TUNING SIZE, DISPERSITY, AND SURFACE CHEMISTRY FOR DRUG DELIVERY | TRUSTEES OF TUFTS COLLEGE (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20240082405-A1 | Low Molecular Weight Silk Compositions and Stabilizing Silk Compositions | TRUSTEES OF TUFTS COLLEGE | 2024-03-14 | — | — | US | disclosed |
| US-20230404959-A1 | TOPICAL FORMULATION COMPRISING OMEGA-3 FATTY ACIDS, MELATONIN AND VITAMIN D | AMBO INNOVATIONS LLC | 2023-12-21 | — | — | US | disclosed |
| EP-3274004-B1 | CONTROLLED RELEASE MATRIX BARRIER STRUCTURE FOR SUBCUTANEOUS MEDICAL DEVICES | SURMODICS INC (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2023220273-A1 | TOPICAL FORMULATION COMPRISING OMEGA-3 FATTY ACIDS, MELATONIN AND VITAMIN D | AMBO INNOVATIONS LLC (US) | 2023-11-16 | — | — | WO | disclosed |
| US-11771767-B2 | Reduced and oxidized polysaccharides and methods of use thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-10-03 | — | — | US | disclosed |
| EP-4240325-A1 | TOPICAL FORMULATION COMPRISING OMEGA-3 FATTY ACIDS, MELATONIN AND VITAMIN D | Ambo Innovation LLC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-11701429-B2 | Targeted drug delivery through affinity based linkers | Akamara Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-6268222-B1 | Microparticles attached to nanoparticles labeled with flourescent dye | LUMINEX CORPORATION | 2001-07-31 | — | — | US | disclosed |
| US-20010006817-A1 | CELL DELIVERY COMPOSITIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2001-07-05 | — | — | US | disclosed |
| WO-2001013120-A1 | MICROPARTICLES WITH MULTIPLE FLUORESCENT SIGNALS AND METHODS OF USING SAME | LUMINEX CORPORATION (US) | 2001-02-22 | — | — | WO | disclosed |
| EP-1049807-A1 | MICROPARTICLES WITH MULTIPLE FLUORESCENT SIGNALS | Luminex Corporation (US) | 2000-11-08 | — | — | EP | disclosed |
| WO-2000063409-A1 | ENDOSOMOLYTIC AGENTS AND CELL DELIVERY SYSTEMS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2000-10-26 | — | — | WO | disclosed |
| US-6107499-A | FACILITATING THE TRANSPORT OF A NEUROTRANSMITTER ACROSS THE BLOOD BRAIN BARRIER BY ADMINISTERING THE DRUG, A NEUROTRANSMITTER SUCH AS DOPAMINE COVALENTLY COUPLED TO A SINGLE, STRAIGHT-CHAINED FATTY ACID CARRIER MOLECULE | NEUROMEDICA, INC. (US) | 2000-08-22 | — | — | US | disclosed |
| WO-1999037814-A9 | MICROPARTICLES WITH MULTIPLE FLUORESCENT SIGNALS | LUMINEX CORP (US) | 1999-10-14 | — | — | WO | disclosed |
| WO-1999042091-A2 | USE OF POLYCATIONS AS ENDOSOMOLYTIC AGENTS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1999-08-26 | — | — | WO | disclosed |
| WO-1999037814-A1 | MICROPARTICLES WITH MULTIPLE FLUORESCENT SIGNALS | LUMINEX CORPORATION (US) | 1999-07-29 | — | — | WO | disclosed |
| US-5840338-A | THERMAL AND CHEMICAL STABILITY | MEDLOGIC GLOBAL LIMITED (GB) | 1998-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771767-B2 | Reduced and oxidized polysaccharides and methods of use thereof | ALG1, LPO, FUT5 | CYP19A1 3841/4885CYP11A1 722/4885CYP3A4 4061/4885 |
| US-11701429-B2 | Targeted drug delivery through affinity based linkers | ABCG2, FCGR2A, ABCB1 | CYP19A1 3272/4885CYP11A1 1891/4885CYP3A4 1428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.